Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

News

Below you will find a list of clinical trials and press releases.


Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases - an Observational Retrospective Cohort Study in Sweden


Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence


Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients


Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer


Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy


Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management


Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer


Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)


Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer


Evaluation of PSA Blood Levels Prior to and After Digital Rectal Examination


ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer


Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer


Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer


A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)


Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer


Prostvac in Patients With Biochemically Recurrent Prostate Cancer


Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone


Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability


A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)


Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs


Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer


A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer


An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS


A Multicenter, Prospective, Longitudinal Registry of Participants With Prostate Cancer


Metformin And Longevity (METAL)


A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement


Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer


Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer


A Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC


Study of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer


Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC


AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)


Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone


A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel Treatment in Patients Who Have Previously Received Enzalutamide


Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer


Radiologically Guided Biopsies of mCRPC


Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate Cancer


Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy


Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY)


A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Previously Been Treated With Enzalutamide
 

Recruitment: Recruiting
Study Results: No Results Available
Conditions: Prostate Cancer|Prostatic Neoplasms|Neoplasms, Prostate
Interventions: Drug: VT-464

A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
 

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostate Cancer
Interventions: Drug: Vismodegib

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
 

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0444, NCT02113657

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
 

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-025, NCT02106507

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
 

Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 10241, NCI-2014-00417, P30CA069533, NCT02099864

Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
 

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SP001, 2011-004735-32, NCT02105675

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
 

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CRP-PCA-01, NCT02097303

A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
 

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostate Cancer
Interventions: Drug: Vismodegib

A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
 

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostate Cancer
Interventions: Drug: Vismodegib

A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
 

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostate Cancer
Interventions: Drug: Vismodegib

A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
 

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostate Cancer
Interventions: Drug: Vismodegib

A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
 

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostate Cancer
Interventions: Drug: Vismodegib

A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
 

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostate Cancer
Interventions: Drug: Vismodegib

A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
 

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostate Cancer
Interventions: Drug: Vismodegib

A Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles in Patients With Castration-resistant Prostate Cancer (CRPC)

Recruitment Recruiting
Study Results No Results Available
Conditions Prostate Cancer
Interventions  Drug: Melphalan|Drug: Lenograstim
Sponsor/Collaborators Queen Mary University of London

 
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Recruitment Recruiting
Study Results No Results Available
Conditions Castration-resistant Prostate Cancer|CRPC
Interventions Drug: VT-464: given orally once daily in 28 day cycles
Sponsor/Collaborators  Innocrin Pharmaceutical

Press release :

ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer

Recruitment:

Not yet recruiting

Study Results:

No Results Available

Conditions: 

Cancer|Prostate Cancer

Interventions: 

Drug: ADXS31-142|Drug: ADXS31-142 + Pembrolizumab (MK-3475)

Sponsor/Collaborators:

Advaxis, Inc.|Merck Sharp & Dohme Corp.

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate

Recruitment: 

Recruiting

Study Results: 

No Results Available

Conditions: 

Nonmetastatic Castration-Resistant Prostate Cancer|Prostate Cancer|Cancer of the Prostate

Interventions:

Drug: Enzalutamide|Drug: Placebo|Drug: Leuprolide

Sponsor/Collaborators: 

Medivation, Inc.|Astellas Pharma Inc

A Drug Utilization Study of Radium-223 in Sweden

Recruitment: 

Not yet recruiting

Study Results: 

No Results Available

Conditions:

Neoplasms

Interventions:

Other: Radium - 223 (Xofigo)

Sponsor/Collaborators:

Bayer

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

Recruitment: 

Not yet recruiting

Study Results: 

No Results Available

Conditions: 

Prostate Cancer

Interventions: 

Drug: Enzalutamide|Drug: Metformin Hydrochloride|Other: Laboratory Biomarker Analysis

Sponsor/Collaborators:

University of California, Davis|National Cancer Institute (NCI)|Medivation, Inc.|Astellas Pharma Inc

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Recruitment: Not yet recruiting
Study Results:  No Results Available
Conditions: Hormone-Resistant Prostate Cancer|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer
Interventions: Biological: Pembrolizumab|Drug: Enzalutamide|Other: Laboratory Biomarker Analysis
Sponsor/Collaborators: OHSU Knight Cancer Institute|National Cancer Institute (NCI)

Carboplatin in Castration-resistant Prostate Cancer

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostatic Neoplasm
Interventions: Drug: Carboplatin
Sponsor/Collaborators:  Aurelius Omlin|Teva Pharma|University Hospital, Zürich|Cantonal Hospital of St. Gallen

Efficacy and Safety Study of ODM-201 in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostate Cancer Non-Metastatic Castration-Resistant
Interventions: Drug: ODM-201|Drug: Placebo
Sponsor: Orion Corporation, Orion Pharma|Bayer

Phase III Radium 223 mCRPC-PEACE III

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostate Cancer
Interventions: Drug: Ra223|Drug: Enzalutamide
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Prostate Cancer
Interventions: Drug: Docetaxel| Drug: Prednisone|Drug: LDE225
Sponsor: Hackensack University Medical Center|Martin Gutierrez|Novartis

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

Recruitment: Recruiting
Study Results: No Results Available
Conditions: Lung Cancer | Breast Cancer | Prostate Cancer | Tumors (Others)
Interventions: Biological: MVA-brachyury- TRICOM
Sponsor: National Institutes of Health Clinical Center (CC) | National Cancer Institute (NCI)

 

Share

E-Alert

Register to be notified when new content is published. Only your name, country and email address needed.

Subscribe »

EAU 2016 Scientific Programme and Sessions

View the Scientific Programme and Sessions of the 2016 EAU Annual Congress, Munich, Germany.

The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.
The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views

Search this site

Search form